HALO Halozyme Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

HALO [NASD]

Halozyme Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	268.89	EPS (ttm)	0.15	Insider Own	0.70%	Shs Outstand	136.58M	Perf Week	5.46%
Market Cap	5.44B	Forward P/E	23.59	EPS next Y	1.74	Insider Trans	-18.59%	Shs Float	130.36M	Perf Month	38.10%
Income	21.50M	PEG	4.64	EPS next Q	0.46	Inst Own	-	Short Float	10.32%	Perf Quarter	47.99%
Sales	199.60M	P/S	27.24	EPS this Y	10.50%	Inst Trans	-1.75%	Short Ratio	7.38	Perf Half Y	69.51%
Book/sh	0.72	P/B	57.14	EPS next Y	103.74%	ROA	4.10%	Target Price	36.73	Perf Year	110.65%
Cash/sh	2.62	P/C	15.68	EPS next 5Y	58.00%	ROE	24.30%	52W Range	12.71 - 41.26	Perf YTD	132.04%
Dividend	-	P/FCF	-	EPS past 5Y	2.10%	ROI	-13.70%	52W High	-0.29%	Beta	1.74
Dividend %	-	Quick Ratio	16.40	Sales past 5Y	21.10%	Gross Margin	83.10%	52W Low	223.68%	ATR	1.73
Employees	132	Current Ratio	18.50	Sales Q/Q	41.30%	Oper. Margin	17.30%	RSI (14)	75.20	Volatility	4.16% 4.85%
Optionable	Yes	Debt/Eq	3.98	EPS Q/Q	248.90%	Profit Margin	10.80%	Rel Volume	0.95	Prev Close	40.69
Shortable	Yes	LT Debt/Eq	3.98	Earnings	Nov 02 AMC	Payout	0.00%	Avg Volume	1.82M	Price	41.14
Recom	2.30	SMA20	14.64%	SMA50	32.21%	SMA200	61.23%	Volume	1,731,053	Change	1.11%

Sep-14-20

Resumed

JP Morgan

Overweight

$28

Jul-01-20

Initiated

The Benchmark Company

Buy

$39

Feb-05-20

Upgrade

Piper Sandler

Neutral → Overweight

$18 → $27

Jan-09-20

Upgrade

BMO Capital Markets

Market Perform → Outperform

$17 → $24

Jan-08-20

Initiated

Goldman

Buy

$24

Nov-05-19

Upgrade

Barclays

Underweight → Equal Weight

$17 → $16

Oct-19-18

Resumed

Piper Jaffray

Neutral

May-11-18

Downgrade

Barclays

Equal Weight → Underweight

$19

Jan-24-18

Initiated

Goldman

Neutral

Oct-16-17

Reiterated

Piper Jaffray

Overweight

$26 → $29

Jan-06-17

Downgrade

Citigroup

Buy → Neutral

Nov-03-16

Initiated

Deutsche Bank

Buy

$12

Dec-04-15

Initiated

Wells Fargo

Outperform

Nov-18-15

Initiated

Citigroup

Buy

Sep-22-15

Initiated

Barclays

Overweight

$27

Jun-22-15

Reiterated

JP Morgan

Overweight

$20 → $25

Mar-03-15

Reiterated

UBS

Buy

$16 → $21

Feb-18-15

Reiterated

MLV & Co

Buy

$15 → $20

Jan-08-15

Reiterated

MLV & Co

Buy

$12 → $15

Dec-24-14

Initiated

MLV & Co

Buy

$12

Nov-25-20 01:14PM	Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer Zacks
Nov-24-20 03:08PM	Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology Zacks
Nov-23-20 09:12AM	A Look Into Halozyme Therapeutics's Debt Benzinga
08:05AM	Halozyme Raises Full Year 2020 Guidance PR Newswire
08:00AM	Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
Nov-18-20 04:01PM	Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire
Nov-17-20 01:16PM	Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study Zacks
Nov-13-20 09:59AM	Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer PR Newswire
Nov-12-20 08:15AM	Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma PR Newswire
Nov-05-20 06:40PM	MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 PR Newswire
08:15AM	Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® PR Newswire
Nov-04-20 06:54AM	Halozyme Therapeutics, Inc. Just Recorded A 24% EPS Beat: Here's What Analysts Are Forecasting Next Simply Wall St.
Nov-03-20 04:14PM	Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High Investor's Business Daily +11.34%
09:52AM	Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks
Nov-02-20 11:31PM	Halozyme Therapeutics Inc (HALO) Q3 2020 Earnings Call Transcript Motley Fool
05:55PM	Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates Zacks
04:01PM	Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance PR Newswire
Oct-26-20 12:31PM	Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-22-20 07:30PM	argenx SE (ARGX) Q3 2020 Earnings Call Transcript Motley Fool
Oct-21-20 08:38AM	How Much Did Halozyme Therapeutics' (NASDAQ:HALO) CEO Pocket Last Year? Simply Wall St.
Oct-20-20 03:16PM	Stocks Up Nearly 1% Before Fading; Three Breakouts To Watch Investor's Business Daily
Oct-06-20 02:14AM	Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology PR Newswire
Sep-28-20 10:40AM	Hedge Funds Are Getting Bullish On Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Sep-17-20 08:00AM	Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer PR Newswire
Sep-10-20 08:01AM	Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis PR Newswire
Sep-09-20 11:30AM	Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound? Zacks
08:01AM	Halozyme To Present At Upcoming Virtual Investor Conferences PR Newswire
Sep-02-20 04:01PM	Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference PR Newswire
Aug-11-20 11:18AM	Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates Zacks
09:00AM	Halozyme Therapeutics Inc (HALO) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 05:25PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates Zacks
04:01PM	Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results PR Newswire
Aug-04-20 04:05PM	Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference PR Newswire
Aug-03-20 12:31PM	Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jul-29-20 04:05PM	Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call PR Newswire
Jul-28-20 12:32PM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? Zacks
Jul-23-20 09:49AM	Should You Take Comfort From Insider Transactions At Halozyme Therapeutics, Inc. (NASDAQ:HALO)? Simply Wall St.
Jul-17-20 01:30PM	Did Hedge Funds Make The Right Call On Halozyme Therapeutics, Inc. (HALO) ? Insider Monkey
Jul-09-20 02:46PM	Drug Stock May Be Overdue for a Short Squeeze Schaeffer's Investment Research
Jul-01-20 07:20PM	Edited Transcript of HALO.OQ earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-29-20 12:54PM	Halozyme Announces Roche Receives FDA Approval For Phesgo (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer PR Newswire
Jun-22-20 08:00AM	Halozyme To Receive $10 Million Milestone Payment From Janssen PR Newswire
Jun-19-20 08:32AM	Why Halozyme Therapeutics (HALO) Stock Might be a Great Pick Zacks
Jun-17-20 05:08PM	Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference PR Newswire
Jun-16-20 10:01AM	Here is What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Jun-13-20 07:09AM	Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress PR Newswire
Jun-10-20 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report? Zacks
Jun-04-20 12:35PM	Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma PR Newswire
May-29-20 10:28AM	Is Halozyme Therapeutics (HALO) a Smart Long-term Buy? Insider Monkey
May-28-20 08:01AM	Halozyme To Present At Upcoming Virtual Investor Conferences PR Newswire
May-20-20 08:32AM	Why Halozyme (HALO) Could Be Positioned for a Surge Zacks
May-19-20 08:37AM	Why Halozyme (HALO) Stock Might be a Great Pick Zacks
May-15-20 11:25AM	Top Ranked Momentum Stocks to Buy for May 15th Zacks
May-14-20 04:01PM	Halozyme To Receive $15 Million Milestone Payment From Janssen PR Newswire
May-13-20 03:18AM	Barclays Sticks to Their Hold Rating for Halozyme Therapeutics Investing.com
May-12-20 09:52AM	Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates Zacks
04:31AM	Halozyme Therapeutics Inc (HALO) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 06:35PM	Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue Estimates Zacks +5.12%
04:01PM	Halozyme Reports First Quarter 2020 Results PR Newswire
11:50AM	Halozyme Therapeutics (HALO) Stock Is Absurdly Cheap Right Now Insider Monkey
May-08-20 10:34AM	Will Halozyme Therapeutics Continue to Surge Higher? Zacks
May-07-20 08:01AM	Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference PR Newswire
May-01-20 03:16PM	Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma PR Newswire
Apr-30-20 04:56PM	Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma PR Newswire
Apr-28-20 05:05PM	Halozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call PR Newswire
12:33PM	Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-26-20 09:40PM	Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma PR Newswire
Apr-13-20 08:44AM	What You Must Know About Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Beta Value Simply Wall St.
Apr-03-20 08:00AM	Halozyme Announces Change Of Location Of Annual Stockholders' Meeting PR Newswire
Mar-29-20 05:44PM	Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock? Insider Monkey
Mar-25-20 11:30AM	Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-19-20 10:30AM	Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now? Zacks +7.19%
Mar-05-20 06:36PM	Edited Transcript of HALO earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-20 08:39AM	Surging Earnings Estimates Signal Good News for Halozyme (HALO) Zacks
Feb-27-20 07:37AM	Halozyme Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-26-20 04:01PM	Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference PR Newswire
Feb-25-20 10:05AM	Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates Zacks
01:20AM	Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology PR Newswire
Feb-24-20 05:45PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:02PM	Halozyme Reports Fourth Quarter and Full Year 2019 Results PR Newswire
04:01PM	Halozyme Announces CFO Transition PR Newswire
Feb-17-20 12:30PM	Earnings Preview: Halozyme Therapeutics (HALO) Q4 Earnings Expected to Decline Zacks
Feb-10-20 04:01PM	Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call PR Newswire
Feb-06-20 08:25AM	Is Halozyme Therapeutics (NASDAQ:HALO) Using Debt In A Risky Way? Simply Wall St.
Jan-14-20 08:00AM	Halozyme Provides 2020 Business Update And Financial Guidance PR Newswire +5.91%
Jan-03-20 08:00AM	Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-12-19 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report? Zacks
02:00AM	Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium PR Newswire
Dec-06-19 10:02AM	Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Nov-20-19 05:28PM	Edited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-19 10:09AM	The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga
Nov-14-19 08:27AM	Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session Zacks
Nov-13-19 10:57PM	Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire +5.37%
09:06AM	Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3 Zacks
Nov-12-19 05:45PM	Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:30PM	Bernadette Connaughton Appointed to Syneos Health Board of Directors GlobeNewswire
04:10PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire
04:01PM	Halozyme Reports Third Quarter 2019 Results PR Newswire
Nov-07-19 12:56PM	Long-Term Signal Says Buy This Biotech Schaeffer's Investment Research
Nov-05-19 10:32AM	Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +10.46%

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	President and CEO	Nov 25	Option Exercise	14.66	50,000	733,000	530,522	Nov 25 06:56 PM
Daly James M	Director	Nov 25	Sale	40.41	10,363	418,800	21,002	Nov 25 06:57 PM
Henderson Jeffrey William	Director	Nov 25	Sale	40.08	24,498	981,757	47,609	Nov 25 06:59 PM
Torley Helen	President and CEO	Nov 25	Sale	40.73	50,000	2,036,568	480,522	Nov 25 06:56 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Nov 20	Sale	38.76	12,000	465,176	134,800	Nov 20 06:25 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Oct 20	Sale	30.43	12,000	365,148	146,800	Oct 20 04:53 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Sep 21	Sale	26.91	12,000	322,884	158,800	Sep 21 07:30 PM
MATSUI CONNIE	Director	Sep 11	Sale	27.06	32,000	865,792	216,753	Sep 14 05:33 PM
Matsuda Masaru	SVP, General Counsel	Sep 04	Option Exercise	0.00	6,884	0	13,822	Sep 04 06:13 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Aug 20	Sale	28.30	12,000	339,564	170,800	Aug 20 04:21 PM
Daly James M	Director	Aug 13	Sale	29.12	34,337	999,893	31,365	Aug 13 06:43 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Jul 20	Sale	29.01	12,000	348,072	182,800	Jul 20 06:33 PM
LaBarre Michael J.	SVP, Chief Technical Officer	May 22	Option Exercise	7.14	18,613	132,897	194,800	May 22 06:39 PM
LaBarre Michael J.	SVP, Chief Technical Officer	May 20	Option Exercise	7.14	21,387	152,703	197,574	May 21 04:11 PM
LaBarre Michael J.	SVP, Chief Technical Officer	May 20	Sale	23.80	21,387	509,075	176,187	May 21 04:11 PM
Kelley Kenneth J	Director	Mar 19	Buy	14.23	52,629	748,697	277,553	Mar 19 07:28 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Feb 22	Option Exercise	0.00	8,803	0	179,231	Feb 24 08:04 PM
Stelzer Laurie	SVP, Chief Financial Officer	Feb 22	Option Exercise	0.00	11,392	0	120,675	Feb 24 08:03 PM
Torley Helen	President and CEO	Feb 22	Option Exercise	0.00	39,354	0	510,033	Feb 24 08:02 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Feb 14	Option Exercise	0.00	5,772	0	172,423	Feb 18 04:16 PM
Stelzer Laurie	SVP, Chief Financial Officer	Feb 14	Option Exercise	0.00	7,809	0	111,983	Feb 18 04:15 PM
Torley Helen	President and CEO	Feb 14	Option Exercise	0.00	28,730	0	484,923	Feb 18 04:14 PM
Matsuda Masaru	SVP, General Counsel	Feb 12	Option Exercise	0.00	4,130	0	8,619	Feb 13 06:41 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Feb 12	Option Exercise	0.00	7,883	0	169,376	Feb 13 06:39 PM
Stelzer Laurie	SVP, Chief Financial Officer	Feb 12	Option Exercise	0.00	11,262	0	108,068	Feb 13 06:38 PM
Torley Helen	President and CEO	Feb 12	Option Exercise	0.00	32,795	0	472,452	Feb 13 06:24 PM
LaBarre Michael J.	SVP, Chief Technical Officer	Feb 03	Option Exercise	0.00	11,559	0	165,782	Feb 04 04:24 PM
Stelzer Laurie	SVP, Chief Financial Officer	Feb 03	Option Exercise	0.00	23,119	0	105,081	Feb 04 04:21 PM
Torley Helen	President and CEO	Feb 03	Option Exercise	0.00	55,487	0	459,567	Feb 04 04:18 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience